0.91
+0.0069(+0.76%)
Currency In USD
| Previous Close | 0.9 |
| Open | 0.9 |
| Day High | 0.95 |
| Day Low | 0.89 |
| 52-Week High | 2.59 |
| 52-Week Low | 0.49 |
| Volume | 102,079 |
| Average Volume | 176,322 |
| Market Cap | 81.63M |
| PE | -2.12 |
| EPS | -0.43 |
| Moving Average 50 Days | 0.83 |
| Moving Average 200 Days | 0.83 |
| Change | 0.01 |
If you invested $1000 in Context Therapeutics Inc. (CNTX) since IPO date, it would be worth $178.43 as of September 29, 2025 at a share price of $0.91. Whereas If you bought $1000 worth of Context Therapeutics Inc. (CNTX) shares 3 years ago, it would be worth $819.82 as of September 29, 2025 at a share price of $0.91.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting
GlobeNewswire Inc.
Jun 02, 2025 11:30 AM GMT
Dosing cohort 3 of Phase 1 trial of CTIM-76, a Claudin 6 x CD3 T cell engager Expect to share initial data in the first half of 2026 PHILADELPHIA, June 02, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX),
Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer
GlobeNewswire Inc.
May 29, 2025 11:30 AM GMT
PHILADELPHIA, May 29, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced the appoi
Context Therapeutics Reports First Quarter 2025 Operating and Financial Results
GlobeNewswire Inc.
May 07, 2025 8:09 PM GMT
CTIM-76 and CT-95 in Phase 1 Clinical Trials Cash and cash equivalents of $89.4 million as of March 31, 2025 Company expects its cash and cash equivalents will continue to fund operations into 2027 PHILADELPHIA, May 07, 2025 (GLOBE NEWSWIRE) -- Con